NVAX
Novavax Inc
10.60$
+0.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +8.5% | -24.7% | +34.4% | -5.8% | -8.9% | -17.1% | +3.4% | -11.7% | -0.3% | -11.3% | -8.4% | |
| – | +13.6% | -36.4% | +65.5% | -8.3% | +2.3% | -23.1% | +5.9% | +6.0% | +0.4% | -13.0% | -9.4% | |
| – | -12.7% | -15.5% | +41.5% | -15.7% | -7.6% | -50.3% | -3.6% | +5.6% | -10.2% | -5.1% | -16.2% | |
| – | -12.7% | -15.5% | +118.4% | -13.3% | +1.5% | -20.8% | -16.3% | +24.6% | -3.6% | +7.5% | -9.0% | |
| – | +140.4% | -92.8% | +50.2% | +195.8% | +14.0% | -58.9% | +408.6% | -84.9% | +211.5% | -78.1% | -19.6% | |
| – | -40.1% | -62.2% | -41.9% | -5.8% | +1.3% | +17.3% | -0.2% | +31.9% | -14.6% | -0.8% | -12.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.0% | -3.4% | +0.2% | +2.7% | -15.2% | +4.2% | +0.8% | +0.1% | +0.3% | -0.5% | -0.3% | |
| – | +7.7% | -11.7% | +1.3% | -0.5% | -2.4% | -37.3% | -5.1% | +2.9% | -2.4% | -8.9% | -3.5% | |
| – | +11.3% | -50.8% | +43.9% | +2.0% | -2.3% | -63.4% | -7.8% | +10.5% | +7.0% | -25.5% | -3.5% | |
| – | +286.0% | +22.3% | +49.8% | +2.6% | -27.6% | -21.8% | +1.4% | -9.3% | -50.2% | -15.8% | +94.6% | |
| – | +30.1% | -56.5% | +38.5% | -28.1% | -27.7% | -17.8% | +48.1% | -69.9% | +61.4% | -34.5% | +42.5% | |
| – | +0.2% | +0.2% | +0.2% | +0.2% | +0.2% | +0.3% | +0.3% | +43.0% | +0.2% | +19.2% | +0.2% | |
| – | – | – | – | – | – | – | – | -516.4% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +19.6% | +13.1% | +18.5% | -3.5% | +0.1% | +10.8% | -0.2% | -8.4% | +6.6% | -5.7% | +0.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.